References
1.	Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-788.
2.	ACEON® (perindopril erbumine) Tablets. [Prescribing Information]. Marietta, GA: Solvay Pharmaceuticals, Inc.; Rev 5/2005. ©2005 Solvay Pharmaceuticals, Inc.
3.	Myers MG. A dose-response study of perindopril in hypertension: effects on blood pressure 6 and 24 h after dosing. Perindopril Multicentre Dose-Response Study Group. Can J Cardiol. 1996;12:1191-1196.
4.	National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. NIH Publication No. 04-5230. August 2004. Available at http://www.nhlbi.nih.gov/guidelines/hypertension/jncintro.htm. Accessed May 23, 2005.
5.	Speirs C, Wagniart F, Poggi L. Perindopril postmarketing surveillance: a 12 month study in 47,351 hypertensive patients. Br J Clin Pharmacol. 1998;46:63-70.